GLPwatch
At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
JAMA · 2024
Last updated 2026-05-28| Journal | JAMA, 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.25 |
| NIH percentile | 16 |
| Molecules | semaglutide, tirzepatide, retatrutide |
| Conditions studied | Obesity |
Full record and abstract on PubMed 38055301 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.